These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

596 related items for PubMed ID: 7931470

  • 1. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
    Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, Edison M, Phelps RM, Lesar M, Phares JC.
    J Clin Oncol; 1994 Oct; 12(10):2022-34. PubMed ID: 7931470
    [Abstract] [Full Text] [Related]

  • 2. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
    Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie T, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A.
    J Clin Oncol; 2006 May 01; 24(13):2038-43. PubMed ID: 16648503
    [Abstract] [Full Text] [Related]

  • 3. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
    Mavroudis D, Papadakis E, Veslemes M, Tsiafaki X, Stavrakakis J, Kouroussis C, Kakolyris S, Bania E, Jordanoglou J, Agelidou M, Vlachonicolis J, Georgoulias V, Greek Lung Cancer Cooperative Group.
    Ann Oncol; 2001 Apr 01; 12(4):463-70. PubMed ID: 11398877
    [Abstract] [Full Text] [Related]

  • 4. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
    Miller AA, Herndon JE, Hollis DR, Ellerton J, Langleben A, Richards F, Green MR.
    J Clin Oncol; 1995 Aug 01; 13(8):1871-9. PubMed ID: 7636529
    [Abstract] [Full Text] [Related]

  • 5. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA.
    Clin Cancer Res; 1999 Nov 01; 5(11):3419-24. PubMed ID: 10589753
    [Abstract] [Full Text] [Related]

  • 6. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M, Havemann K, Holle R, Gropp C, Drings P, Hans K, Schroeder M, Heim M, Dommes M, Mende S.
    J Clin Oncol; 1987 Dec 01; 5(12):1880-9. PubMed ID: 2824710
    [Abstract] [Full Text] [Related]

  • 7. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.
    Pujol JL, Douillard JY, Rivière A, Quoix E, Lagrange JL, Berthaud P, Bardonnet-Comte M, Polin V, Gautier V, Milleron B, Chomy F, Chomy P, Spaeth D, Le Chevalier T.
    J Clin Oncol; 1997 May 01; 15(5):2082-9. PubMed ID: 9164221
    [Abstract] [Full Text] [Related]

  • 8. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
    Tabata M, Kiura K, Okimoto N, Segawa Y, Shinkai T, Yonei T, Kuyama S, Harita S, Hotta K, Ueoka H, Tanimoto M.
    Cancer Chemother Pharmacol; 2007 Jun 01; 60(1):1-6. PubMed ID: 17393168
    [Abstract] [Full Text] [Related]

  • 9. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
    Murray N, Livingston RB, Shepherd FA, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin JW, Grafton C, Turrisi A, Walde D, Croft H, Osoba D, Ottaway J, Gandara D.
    J Clin Oncol; 1999 Aug 01; 17(8):2300-8. PubMed ID: 10561291
    [Abstract] [Full Text] [Related]

  • 10. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K, Fukuoka M, Nishiwaki Y, Kurita Y, Watanabe K, Noda K, Ariyoshi Y, Tamura T, Saijo N.
    J Clin Oncol; 1998 Jun 01; 16(6):2126-32. PubMed ID: 9626212
    [Abstract] [Full Text] [Related]

  • 11. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
    Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS.
    Clin Lung Cancer; 2003 Jul 01; 5(1):40-5. PubMed ID: 14596703
    [Abstract] [Full Text] [Related]

  • 12. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.
    Niell HB, Herndon JE, Miller AA, Watson DM, Sandler AB, Kelly K, Marks RS, Perry MC, Ansari RH, Otterson G, Ellerton J, Vokes EE, Green MR, Cancer and Leukemia Group.
    J Clin Oncol; 2005 Jun 01; 23(16):3752-9. PubMed ID: 15923572
    [Abstract] [Full Text] [Related]

  • 13. Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group.
    Ignatiadis M, Mavroudis D, Veslemes M, Boukovinas J, Syrigos K, Agelidou M, Agelidou A, Gerogianni A, Pavlakou G, Tselepatiotis E, Nikolakopoulos J, Georgoulias V.
    Clin Lung Cancer; 2005 Nov 01; 7(3):183-9. PubMed ID: 16354313
    [Abstract] [Full Text] [Related]

  • 14. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY, Cho KH, Lee DH, Kim HY, Kim EA, Lee SY, Lee JS.
    J Clin Oncol; 2005 May 20; 23(15):3488-94. PubMed ID: 15908658
    [Abstract] [Full Text] [Related]

  • 15. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study.
    Pujol JL, Daurès JP, Rivière A, Quoix E, Westeel V, Quantin X, Breton JL, Lemarié E, Poudenx M, Milleron B, Moro D, Debieuvre D, Le Chevalier T.
    J Natl Cancer Inst; 2001 Feb 21; 93(4):300-8. PubMed ID: 11181777
    [Abstract] [Full Text] [Related]

  • 16. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
    Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S, Norwegian Lung Cancer Study Group.
    J Clin Oncol; 2002 Dec 15; 20(24):4665-72. PubMed ID: 12488411
    [Abstract] [Full Text] [Related]

  • 17. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial.
    Johnson DH, Greco FA, Strupp J, Hande KR, Hainsworth JD.
    J Clin Oncol; 1990 Oct 15; 8(10):1613-7. PubMed ID: 2170589
    [Abstract] [Full Text] [Related]

  • 18. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group.
    Johnson DH, Bass D, Einhorn LH, Crawford J, Perez CA, Bartolucci A, Omura GA, Greco FA.
    J Clin Oncol; 1993 Jul 15; 11(7):1223-9. PubMed ID: 8391064
    [Abstract] [Full Text] [Related]

  • 19. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.
    Ardizzoni A, Tjan-Heijnen VC, Postmus PE, Buchholz E, Biesma B, Karnicka-Mlodkowska H, Dziadziuszko R, Burghouts J, Van Meerbeeck JP, Gans S, Legrand C, Debruyne C, Giaccone G, Manegold C, European Organization for Research and Treatment of Cancer-Lung Cancer Group.
    J Clin Oncol; 2002 Oct 01; 20(19):3947-55. PubMed ID: 12351591
    [Abstract] [Full Text] [Related]

  • 20. Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer.
    Murray N, Shah A, Osoba D, Page R, Karsai H, Grafton C, Goddard K, Fairey R, Voss N.
    J Clin Oncol; 1991 Sep 01; 9(9):1632-8. PubMed ID: 1651995
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.